Subscribe to RSS
DOI: 10.1055/s-0042-1749067
Sentinel Lymph Node Biopsy in Endometrial Cancer – A Systematic Review and Quality Assessment of Meta-Analyses
Biópsia do linfonodo sentinela no câncer de endométrio – Uma revisão sistemática e avaliação da qualidade de meta-análises
Abstract
Objective To assess the quality of recent meta-analyses reviewing the diagnostic utility of sentinel node biopsy in endometrial cancer.
Methods With the MeSH terms endometrial neoplasms and sentinel lymph node biopsy, PubMed and Embase databases were searched on October 21, 2020, and again on November 10, 2021, with meta-analysis and publication date filters set to since 2015. The articles included were classified with the A Measurement Tool to Assess Systematic Reviews (AMSTAR 2) assessment tool.
Results The database searches found 17, 7 of which, after the screening, were selected for full review by the author, finally extracting six meta-analyzes for quality analysis. The rating with the AMSTAR 2 assessment tool found that overall confidence in their results was critically low.
Conclusion This study found that the quality of recent meta-analyses on the utility of the staging of endometrial cancer with sentinel node biopsy, evaluated by the AMSTAR 2 assessment tool, is classified as critically low, and, therefore, these meta-analyses are not reliable in the summary of their studies.
Resumo
Objetivo Avaliar a qualidade de meta-análises recentes que revisaram a utilidade diagnóstica da biópsia do linfonodo sentinela no câncer de endométrio.
Métodos Com os termos MeSH endometrial neoplasms e =biópsia do linfonodo sentinela, as bases de dados PubMed e Embase foram pesquisadas em 21 de outubro de 2020 e novamente em 10 de novembro de 2021, com filtros de meta-análise e data de publicação configurados para desde 2015. Os artigos incluídos foram classificados com o instrumento de avaliação A Measurement Tool to Assess Systematic Reviews (AMSTAR 2).
Resultados As pesquisas de banco de dados encontraram 17 artigos, sete dos quais, após a triagem, foram selecionados para revisão completa pelo autor, extraindo finalmente 6 meta-análises para análise de qualidade. A classificação com a ferramenta de avaliação AMSTAR 2 descobriu que a confiança geral em seus resultados era criticamente baixa.
Conclusão Este estudo constatou que a qualidade de meta-análises recentes sobre a utilidade do estadiamento do câncer de endométrio com biópsia do linfonodo sentinela, avaliada pela ferramenta de avaliação AMSTAR 2, é classificada como criticamente baixa e, portanto, essas meta-análises não são confiáveis no resumo de seus estudos.
Palavras-chave
neoplasias - útero - endométrio - linfonodo sentinela - biópsia - neoplasias endometriaisPublication History
Received: 19 November 2021
Accepted: 17 February 2022
Article published online:
20 June 2022
© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet 2018; 143 (Suppl. 02) 37-50 DOI: 10.1002/ijgo.12612.
- 2 Kumar S, Podratz KC, Bakkum-Gamez JN, Dowdy SC, Weaver AL, McGree ME. et al. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol 2014; 132 (01) 38-43 DOI: 10.1016/j.ygyno.2013.10.002.
- 3 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Uterine Neoplasms. Version 1.2021 [Internet]. 2020 [cited 2020 Nov 12]. Available from: https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManager?fileManagerId=11228
- 4 Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J. et al; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (01) 16-41 DOI: 10.1093/annonc/mdv484.
- 5 Benedetti Panici P, Basile S, Maneschi F, Lissoni AA, Signorelli M, Scambia G. et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008; 100 (23) 1707-1716 DOI: 10.1093/jnci/djn397.
- 6 Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373 (9658): 125-136 DOI: 10.1016/S0140-6736(08)61766-3.
- 7 Beesley VL, Rowlands IJ, Hayes SC, Janda M, O'Rourke P, Marquart L. et al; Australian National Endometrial Cancer Study Group. Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecol Oncol 2015; 136 (01) 87-93 DOI: 10.1016/j.ygyno.2014.11.006.
- 8 Abu-Rustum NR. Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging. J Natl Compr Canc Netw 2014; 12 (02) 288-297 DOI: 10.6004/jnccn.2014.0026.
- 9 Geppert B, Lönnerfors C, Bollino M, Persson J. Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications. Gynecol Oncol 2018; 148 (03) 491-498 DOI: 10.1016/j.ygyno.2017.12.017.
- 10 Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J. et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017; 358: j4008 DOI: 10.1136/bmj.j4008.
- 11 Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L, Sehouli J. et al. Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes—a meta-analysis. Ann Surg Oncol 2016; 23 (11) 3749-3756 DOI: 10.1245/s10434-016-5236-x.
- 12 Marchocki Z, Cusimano MC, Clarfield L, Kim SR, Fazelzad R, Espin-Garcia O. et al. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol 2021; 225 (04) 367.e1-367.e39 DOI: 10.1016/j.ajog.2021.05.034.
- 13 Wang L, Liu F. Meta-analysis of laparoscopy sentinel lymph node mapping in endometrial cancer. Arch Gynecol Obstet 2018; 298 (03) 505-510 DOI: 10.1007/s00404-018-4845-y.
- 14 Lin H, Ding Z, Kota VG, Zhang X, Zhou J. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Oncotarget 2017; 8 (28) 46601-46610 DOI: 10.18632/oncotarget.16662.
- 15 Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216 (05) 459-476.e10 DOI: 10.1016/j.ajog.2016.11.1033.
- 16 Gu Y, Cheng H, Zong L, Kong Y, Xiang Y. Operative and oncological outcomes comparing sentinel node mapping and systematic lymphadenectomy in endometrial cancer staging: meta-analysis with trial sequential analysis. Front Oncol 2021; 10: 580128 DOI: 10.3389/fonc.2020.580128.
- 17 Bogani G, Murgia F, Ditto A, Raspagliesi F. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol 2019; 153 (03) 676-683 DOI: 10.1016/j.ygyno.2019.03.254.
- 18 Lu KH, Broaddus RR. Endometrial Cancer. N Engl J Med 2020; 383 (21) 2053-2064 DOI: 10.1056/NEJMra1514010.
- 19 Qiu SQ, Zhang GJ, Jansen L, de Vries J, Schröder CP, de Vries EGE, van Dam GM. Evolution in sentinel lymph node biopsy in breast cancer. Crit Rev Oncol Hematol 2018; 123: 83-94 DOI: 10.1016/j.critrevonc.2017.09.010.
- 20 Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V. et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349 (06) 546-553 DOI: 10.1056/NEJMoa012782.
- 21 Sullivan SA, Rossi EC. Sentinel lymph node biopsy in endometrial cancer: a new standard of care?. Curr Treat Options Oncol 2017; 18 (10) 62 DOI: 10.1007/s11864-017-0503-z.
- 22 Ioannidis JP. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q 2016; 94 (03) 485-514 DOI: 10.1111/1468-0009.12210.
- 23 Lorenz RC, Matthias K, Pieper D, Wegewitz U, Morche J, Nocon M. et al. A psychometric study found AMSTAR 2 to be a valid and moderately reliable appraisal tool. J Clin Epidemiol 2019; 114: 133-140 DOI: 10.1016/j.jclinepi.2019.05.028.